Marinus pharmaceuticals inc (MRNS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities
Net loss

-60,310

-54,121

-48,824

-46,128

-43,210

-36,726

-31,352

-24,412

-19,459

-18,898

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-25,059

-

-20,844

-17,550

-15,605

-10,833

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

326

278

228

174

132

127

185

169

148

126

42

36

30

23

0

0

0

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

6

4

5

0

0

0

Stock-based compensation expense

5,712

5,672

5,581

5,412

5,497

4,788

4,274

3,836

3,260

2,880

3,052

3,120

3,085

3,077

3,016

2,813

2,464

2,108

1,803

1,422

1,058

698

0

0

0

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,192

0

0

0

Amortization of debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Loss on disposal of fixed assets

-

-42

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash lease expense

241

225

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash lease liability

19

-131

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premium on investments

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

-

-

-

-

-

-

-

-

-

4

6

7

7

7

0

0

0

-

-

-

-

-

-

-

-

Amortization of discount on investments

-

-

-

-

-

79

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

375

1,480

125

1,272

364

237

606

355

783

779

41

274

-1,735

-1,396

1,153

-458

2,109

947

1,416

2,417

1,805

1,344

0

0

0

Accounts payable and accrued expenses

3,387

890

1,632

5,491

4,610

4,285

4,434

1,361

-1,231

-2,121

-3,265

-4,141

-1,418

-629

2,060

2,671

315

3,540

3,229

1,947

3,002

1,385

0

0

0

Net cash used in operating activities

-51,006

-48,633

-41,558

-36,345

-33,357

-27,842

-23,164

-19,480

-18,116

-18,816

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-22,259

-

-17,048

-14,253

-11,416

-8,589

0

0

0

Cash flows from investing activities
Maturities of short-term investments

3,731

6,994

0

0

0

-

-

-

-

3,922

3,675

4,917

4,969

4,474

0

0

0

-

-

-

-

-

-

-

-

Deposit on property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Purchases of short-term investments

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,705

0

0

0

-

-

-

-

Deposit on property and equipment

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

337

388

435

415

127

83

264

315

332

450

193

381

747

644

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-7,684

3,881

16,840

22,097

24,793

19,917

5,232

-24,463

-23,040

-21,420

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,633

-

0

0

0

-

-

-

-

Cash flows from financing activities
Proceeds from exercise of stock options

344

97

0

0

0

-

-

-

-

-

-

-

-

124

123

262

296

373

473

334

300

128

0

0

0

Financing costs

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments of notes payable

-

-

-

-

-

-

-

-

-

5,247

6,165

3,669

2,921

2,128

0

0

0

-

-

-

-

-

-

-

-

Proceeds from equity offerings, net of offering costs

-

-

-

-

-

-

-

-

-

52,547

52,593

3,281

2,485

-167

0

0

0

-

-

-

-

-

-

-

-

Repayments of short-term bank borrowings

-

-

-

-

-

193

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net cash provided by/(used in) financing activities

68,168

67,968

42,199

42,217

42,231

42,121

64

45,879

45,761

47,589

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

9,478

23,216

17,497

27,969

33,667

34,196

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

28,144

-

4,818

46,646

48,587

48,305

0

0

0

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,252

-

-19,078

30,517

35,647

39,683

0

0

0

Supplemental disclosure of cash flow information
Cash paid for interest

-

-

-

-

-

-

-

-

-

184

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued equity offering costs

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

474

-

0

0

0

-

-

-

-

Payment on notes payable in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Property and equipment in accounts payable and accrued expenses

-

-

-

-

0

-

-

-

-

-

-

-

-227

134

0

0

0

-

-

-

-

-

-

-

-

Operating lease liability

-

3,357

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating right-of-use asset

-

2,458

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-